Last week Verastem presented additional Copiktra data at the Leerinks Health Care Conference followed by a Q&A session by analysts. The webcast can be accessed here. In this article, I discuss the … [Read more...] about Can Verastem Shake the DownTrend?
GALT’s phase 3 study inclusion criteria will be patients diagnosed with NASH-cirrhosis but without varices, and includes an interim analysis. Competition in the NASH-cirrhosis space is lacking. The … [Read more...] about Galectin Blocker is Front Runner in Fight Against NASH-Cirrhosis